Patent US3547753A successfully refreshed from Google Patents.
Patent FR578656A successfully refreshed from Google Patents.
Patent US597189A successfully refreshed from Google Patents.
Patent US5344959A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5344959A Expired / Lapsed US ⏱️ 0.0 years remaining

Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity

Assignee: Allergan Inc
•
Filing: 1993-05-18
•
Granted: 1994-09-06
•
Expires: 2013-05-18
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of the formula ##STR1## wherein m is 1-4; R 1 -R 4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R 5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R 6 is hydrogen, lower alkyl, Cl, Br, I, OR 11 , SR 11 , OCOR 11 , SCOR 11 , NH2, NHR 11 , N(R 11 ) 2 , NHCOR 11 OR NR 11 --COR 11 ; R 20 is independently hydrogen or lower alkyl; A is (CH 2 ) n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR 8 , CONR 9 R 10 , --CH 2 OH, CH 2 OR 11 , CH 2 OCOR 11 , CHO, CH(OR 12 ) 2 , CHOR 13 O, --COR 7 , CR 7 (OR 12 ) 2 , or CR 7 OR 13 O, where R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R 8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R 8 is phenyl or lower alkylphenyl, R 9 and R 10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower aklylphenyl, R 11 is lower alkyl, phenyl or lower alkylphenyl, R 12 is lower alkyl, and R 13 is divalent alkyl radical of 2-5 carbons, have retinoid-like activity.

Inventors

  • 👤 Roshantha A. Chandraratna

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 13:16
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/54; C07F9/5428; C07C; C07C17/00; C07C17/093; C07C17/16; C07C33/00; C07C33/28; C07C33/30; C07C45/00; C07C45/27; C07C45/29; C07C45/292; C07C45/45; C07C45/46; C07C49/00; C07C49/76; C07C49/782; C07C49/792; C07C61/00; C07C61/16; C07C61/39; C07C69/00; C07C69/74; C07C69/743

Claims Analysis

Total Claims: 27
Claim 1
Independent Claim 290 words
A compound of the formula: ##STR6## wherein m is 1-4; R 1 -R 4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R 5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R 6 is hydrogen, lower alkyl, Cl, Br, I, OR 11 , SR 11 , OCOR 11 , SCOR 11 , NH2, NHR 11 , N(R 11 ) 2 , NHCOR 11 OR NR 11 --COR 11 ; R 20 is independently hydrogen or lower alkyl; A is (CH 2 ) n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR 8 , CONR 9 R 10 , --CH 2 OH, CH 2 OR 11 , CH 2 OCOR 11 , CHO, CH(OR 12 ) 2 , CHOR 13 O , --COR 7 , CR 7 (OR 12 ) 2 , or CR 7 OR 13 O , where R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R 8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R 8 is phenyl or lower alkylphenyl, R 9 and R 10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower aklylphenyl, R 11 is lower alkyl, phenyl or lower alkylphenyl, R 12 is lower alkyl, and R 13 is divalent alkyl radical of 2-5 carbons.
Claim 2
Dependent Claim 290 words
A compound of the formula: ##STR6## wherein m is 1-4; R 1 -R 4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R 5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R 6 is hydrogen, lower alkyl, Cl, Br, I, OR 11 , SR 11 , OCOR 11 , SCOR 11 , NH2, NHR 11 , N(R 11 ) 2 , NHCOR 11 OR NR 11 --COR 11 ; R 20 is independently hydrogen or lower alkyl; A is (CH 2 ) n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR 8 , CONR 9 R 10 , --CH 2 OH, CH 2 OR 11 , CH 2 OCOR 11 , CHO, CH(OR 12 ) 2 , CHOR 13 O , --COR 7 , CR 7 (OR 12 ) 2 , or CR 7 OR 13 O , where R 7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R 8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R 8 is phenyl or lower alkylphenyl, R 9 and R 10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower aklylphenyl, R 11 is lower alkyl, phenyl or lower alkylphenyl, R 12 is lower alkyl, and R 13 is divalent alkyl radical of 2-5 carbons.
Claim 3
Dependent Claim 16 words
A compound of claim 1 wherein A is (CH 2 ) n and n is 0.
Claim 4
Dependent Claim 21 words
A compound of claim 1 wherein B is COOH or a pharmaceutically acceptable salt thereof, or B is COOR 8 .
Claim 5
Dependent Claim 20 words
A compound of claim 1 where R 2 , R 3 , R 4 , and R 5 are hydrogen.
Claim 6
Dependent Claim 13 words
A compound of claim 1 where R 1 and R 20 are methyl.
Claim 7
Dependent Claim 12 words
A compound of claim 1 where R 6 is methyl or hydrogen.
Claim 8
Dependent Claim 13 words
A compound of claim 1 where the configuration about cyclopropane ring is trans.
Claim 9
Dependent Claim 13 words
A compound of claim 1 where the configuration about cyclopropane ring is cis.
Claim 10
Dependent Claim 22 words
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more compounds set forth in claim 1 as the active ingredient.
Claim 11
Dependent Claim 36 words
A method for treating skin disorders in a mammal which method comprises administering alone or in conjunction with a pharmaceutically acceptable excipient a therapeutically effective amount of one or more compounds set forth in claim 1.
Claim 12
Dependent Claim 34 words
A compound of the formula ##STR7## wherein R.sub. 6 is hydrogen, lower alkyl of 1-6 carbons, Cl, Br, or I, and R 8 is hydrogen, or an alkyl group of 1 to 10 carbons.
Claim 13
Dependent Claim 34 words
A compound of the formula ##STR7## wherein R.sub. 6 is hydrogen, lower alkyl of 1-6 carbons, Cl, Br, or I, and R 8 is hydrogen, or an alkyl group of 1 to 10 carbons.
Claim 14
Dependent Claim 10 words
A compound of claim 11 where R 6 is hydrogen.
Claim 15
Dependent Claim 10 words
A compound of claim 12 where R 8 is ethyl.
Claim 16
Dependent Claim 14 words
The compound of claim 13 where the configuration is cis about the cyclopropane ring.
Claim 17
Dependent Claim 14 words
The compound of claim 13 where the configuration is trans about the cyclopropane ring.
Claim 18
Dependent Claim 10 words
A compound of claim 12 where R 8 is hydrogen.
Claim 19
Dependent Claim 14 words
The compound of claim 16 where the configuration is cis about the cyclopropane ring.
Claim 20
Dependent Claim 14 words
The compound of claim 16 where the configuration is trans about the cyclopropane ring.
Claim 21
Dependent Claim 10 words
A compound of claim 11 where R 6 is methyl.
Claim 22
Dependent Claim 10 words
A compound of claim 19 where R 8 is ethyl.
Claim 23
Dependent Claim 14 words
The compound of claim 20 where the configuration is cis about the cyclopropane ring.
Claim 24
Dependent Claim 14 words
The compound of claim 20 where the configuration is trans about the cyclopropane ring.
Claim 25
Dependent Claim 10 words
A compound of claim 19 where R 8 is hydrogen.
Claim 26
Dependent Claim 14 words
The compound of claim 23 where the configuration is cis about the cyclopropane ring.
Claim 27
Dependent Claim 14 words
The compound of claim 23 where the configuration is trans about the cyclopropane ring.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-09-05 1998-03-07 1998-09-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-09-05 2002-03-07 2002-09-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-09-05 2006-03-07 2006-09-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag